Lima Corporate, an Italian medical device company located in San Daniele del Friuli, Udine, reports that it has installed 100, 000 of its C2 Hip Stems since the product was launched. This puts the company on track to install more than 40, 000 implants of the entire Hip Femoral Prosthesis line by the end of 2014.
Lima Corporate Installs Its 100, 000th Hip Stem

Professor Cremonese of the Ospedale di Cittadella, in Padua, Italy, designed the C2 Hip Stem which, according to the company, has since become an integral part of the Lima Corporate Total Hip Arthroplasty solutions. Officials report that the firm is strongly committed to internationalization. Lima Corporate has 14 foreign subsidiaries worldwide along with production facilities in Italy and the Republic of San Marino.
Professor Cremonese is Director of Orthopaedics and Traumatology at the Veneto Regional Center for the diagnosis and treatment of osteoarthritis of the hip. He has performed more than ten thousand orthopedic surgeries with particular focus on surgery of the shoulder and hip. Professor Cremonese is also a faculty member of the Italian Society of Arthroscopy.
“We expect demand to continue to accelerate next year, ” said Luigi Ferrari, Chief Executive Officer of Lima Corporate. “The C2 Hip Stem is implanted in more than 17 Countries worldwide, supported by over 14 years of clinical history and success remaining one of Lima’s most successful stems. The stem is designed to significantly improve the patient’s quality of life”.

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.